These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 8229736

  • 1. Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.
    Grover GJ, Sleph PG, Dzwonczyk S, McCullough JR.
    J Pharmacol Exp Ther; 1993 Oct; 267(1):102-7. PubMed ID: 8229736
    [Abstract] [Full Text] [Related]

  • 2. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
    Grover GJ, D'Alonzo AJ, Garlid KD, Bajgar R, Lodge NJ, Sleph PG, Darbenzio RB, Hess TA, Smith MA, Paucek P, Atwal KS.
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945
    [Abstract] [Full Text] [Related]

  • 3. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
    Sargent CA, Smith MA, Dzwonczyk S, Sleph PG, Grover GJ.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138
    [Abstract] [Full Text] [Related]

  • 4. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
    Grover GJ, D'Alonzo AJ, Hess T, Sleph PG, Darbenzio RB.
    Cardiovasc Res; 1995 Nov; 30(5):731-8. PubMed ID: 8595620
    [Abstract] [Full Text] [Related]

  • 5. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide.
    Ferdinandy P, Szilvássy Z, Droy-Lefaix MT, Tarrade T, Koltai M.
    Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627
    [Abstract] [Full Text] [Related]

  • 6. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
    Docherty JC, Gunter HE, Kuzio B, Shoemaker L, Yang L, Deslauriers R.
    J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352
    [Abstract] [Full Text] [Related]

  • 7. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
    Tosaki A, Szerdahelyi P, Engelman RM, Das DK.
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
    [Abstract] [Full Text] [Related]

  • 8. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
    Grover GJ, McCullough JR, Henry DE, Conder ML, Sleph PG.
    J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775
    [Abstract] [Full Text] [Related]

  • 9. The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism.
    Grover GJ, D'Alonzo AJ, Sleph PG, Dzwonczyk S, Hess TA, Darbenzio RB.
    J Pharmacol Exp Ther; 1994 May; 269(2):536-40. PubMed ID: 8182522
    [Abstract] [Full Text] [Related]

  • 10. Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448.
    Gomoll AW, Roth RA, Swillo RE, Baird AJ, Sargent CS, Behling RW, Malone HJ, Grover GJ.
    J Pharmacol Exp Ther; 1997 Apr; 281(1):24-33. PubMed ID: 9103476
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448.
    Grover GJ, McCullough JR, D'Alonzo AJ, Sargent CA, Atwal KS.
    J Cardiovasc Pharmacol; 1995 Jan; 25(1):40-50. PubMed ID: 7723352
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate.
    McCullough JR, Normandin DE, Conder ML, Sleph PG, Dzwonczyk S, Grover GJ.
    Circ Res; 1991 Oct; 69(4):949-58. PubMed ID: 1934346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.